RegMed Competitive and Market Intelligence 2/15/12, stocks are mixed, some adding minimally or falling upon sessions turning lower
The 6 W’s: Who, what, where, when, why and what of it …
Today’s Gospel: The market’s having a little bit of trouble … despite the fact that China’s so confident that a Greek deal is going to be done, Stocks remained narrowly mixed Wednesday as … traders juggle the markets concerns, consolidate and watch the movement sideways for a while, which <hopefully> would relieve the … overbought situation.
Mid-Day: The NASDAQ is DOWN -0.49 (-0.02%) to 2931.34 while the Dow is also DOWN -80.83 (+0.63%) to 12,797.45.
Mid-Day Market Commentary: Many traders are staying on the sidelines, stocks are turning in a lackluster performance during … MID-DAY … trading on Wednesday. The major averages continue to turn in a mixed performance on the day after ending the previous session nearly flat. The choppy trading comes as traders continue to keep a close eye on developments overseas amid lingering uncertainty about the financial situation in Europe. While remarks from Chinese officials indicating that the country will continue to invest in EU government debt to help resolve the debt crisis have generated some buying interest but, traders are also weighing possibilities that the second Greek bailout will be delayed.
Who is UP … Mid-Day:
- Athersys (ATHX);
- BioLife Solutions (OTC BB: BLFS);
- Dendreon (DNDN);
- Geron (GERN);
- ImmunoCellular (OTC BB: IMUC);
- International Stem Cell (OTC BB: ISCO);
- Osiris (OSIR);
- ReNeuron (RENE.L);
- StemCells (STEM);
- Tengion (TNGN);
- ThermoGenesis (KOOL) and
- Verastem (VSTM).
What’s new in the regenerative medicine/stem cell market … 1 … things to know today …
Advanced Cell Technology (OTC BB: ACTC) Approval of Wills Eye Institute as additional Site for Stem Cell Clinical Trial for Stargardt’s Disease: Site for Both of ACT’s P1/2 Clinical Trials Using Human Embryonic Stem Cell-Derived RPE Cells for Macular Degeneration. The Wills Eye Institute in Philadelphia has received institutional review board (IRB) approval as a site for the P1/2 clinical trial for Stargardt’s Macular Dystrophy (SMD), a form of juvenile macular degeneration, using human embryonic stem cell (hESC)-derived retinal pigment epithelial (RPE) cells.
